Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A longitudinal study of dual-energy X-ray absorptiometry status in menopausal women with adrenal tumors.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie·2026
Same author

Oncocytic Adrenocortical Carcinoma with Somatic Pathogenic Variants of <i>NF1</i> and <i>TP53</i> Genes in a Young Adult Harboring a Germline Likely Pathogenic Variant in <i>CEL</i> Gene: From Hyperandrogenemia of Dual (Adrenal-Ovarian) Cause to Oocyte Preservation and Mitotane Initiation.

Diagnostics (Basel, Switzerland)·2026
Same author

Comprehensive Evaluation of Uropathogens' AMR in a Romanian Tertiary Center: Male vs. Female Comparison.

Microorganisms·2026
Same author

Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study).

Life (Basel, Switzerland)·2026
Same author

A Real-World Study in Non-Functional Adrenal Tumours: Refining Central DXA Results.

Journal of clinical medicine·2026
Same author

Uropathogens' AMR in Male and Female Romanian Population-A Bi-Center Analysis over 1 Year.

Medicina (Kaunas, Lithuania)·2026

Related Experiment Video

Updated: Oct 9, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.1K

Aggressive prolactinoma (Review).

Ana Valea1,2, Florica Sandru3,4, Aida Petca5,6

  • 1Department of Endocrinology, 'I. Hatieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Experimental and Therapeutic Medicine
|December 22, 2021
PubMed
Summary

Aggressive prolactinoma (APRL) is a challenging pituitary tumor subgroup. Management requires multimodal therapy due to invasion, proliferation, and resistance to standard treatments.

Keywords:
aggressive pituitary tumoraggressive prolactinomacabergolinehypophysectomymensesmenstrual cyclepituitary carcinomaprolactinprolactinomatemozolomide

More Related Videos

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.5K
Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

882

Related Experiment Videos

Last Updated: Oct 9, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.1K
X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.5K
Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

882

Area of Science:

  • Endocrinology
  • Oncology
  • Neurosurgery

Background:

  • Aggressive prolactinoma (APRL) is a distinct subgroup of pituitary tumors, comprising 10% of hypophyseal neoplasia.
  • APRL is characterized by tumor invasion, high proliferation, resistance to standard therapies, and early recurrence.
  • Diagnosis is suggested by elevated prolactin, large tumor size, male sex, young age, and genetic factors (MEN1, AIP, SDHx).

Purpose of the Study:

  • To provide a narrative review of aggressive prolactinoma (APRL) presentation and management.
  • To highlight diagnostic indicators and prognostic factors for APRL.
  • To discuss current and emerging therapeutic strategies for APRL.

Main Methods:

  • Narrative review of literature on aggressive prolactinoma.
  • Analysis of clinical presentation, diagnostic features, and prognostic markers.
  • Evaluation of treatment outcomes for standard and novel therapies.

Main Results:

  • APRL presents with specific clinical and genetic features, and prognostic factors include E-cadherin, MMP-9, and VEGF status.
  • Dopamine agonist resistance, high mitotic count, and Ki-67 index are associated with APRL, but not diagnostic alone.
  • Temozolomide shows efficacy in tumor and prolactin reduction (75%), but normalization is rare (8%); novel agents like somatostatin analogues and checkpoint inhibitors are emerging.

Conclusions:

  • Aggressive prolactinoma is a complex pituitary tumor requiring a multimodal therapeutic approach.
  • Early identification of prognostic factors and tailored treatment strategies are crucial for managing APRL.
  • Ongoing research into novel therapies is essential for improving outcomes in challenging APRL cases.